Genmab Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Revenue Growth: Total revenue increased by 25% year-over-year, reaching $1.9 billion for the first half of 2026.

Operating Profit: Adjusted operating profit grew by 18%.

Product Performance:

EPKINLY: Sales reached $312 million, a 48% increase year-over-year.

TIVDAK: Generated $84 million in sales, reflecting strong performance in the U.S. and launch markets.

Tax Rate: Effective tax rate was 3.6%, influenced by the integration of Merus and the utilization of deferred tax assets.

2Strategic Updates and Business Highlights

Pipeline Progress:

Positive Phase III results for epcoritamab in DLBCL, showing significant improvement in progression-free survival.

European approval for TEPKINLY in follicular lymphoma as the first bispecific therapy for this indication.

Initiation of two new Phase III studies for petosemtamab in colorectal cancer.

Commercial Strategy: Focus on expanding EPKINLY's market presence, with strong uptake in community practices and plans for future launches in early lines of therapy.

3Forward Guidance and Outlook

Updated Financial Guidance:

Revenue expected to be between $4.3 billion and $4.5 billion, reflecting a 19% year-over-year growth at the midpoint.

Operating profit projected to be between $1.1 billion and $1.4 billion.

Operating expenses are expected to increase by only 2%, indicating disciplined capital allocation.

Upcoming Data Readouts: Anticipated Phase III data for Rina-S and petosemtamab in Q4 2026, with potential approvals and launches in 2027.

4Bad News, Challenges, or Points of Concern

Competitive Pressures: The market for EGFR bispecifics is becoming increasingly crowded, with competitors advancing quickly, particularly in head and neck cancer.

Trial Delays: Slight delays in the readout for the petosemtamab second-line trial, now expected in Q1 2027, raised questions about recruitment and endpoint changes.

Regulatory Uncertainty: Ongoing discussions with the FDA regarding confirmatory trials for DLBCL indicate potential regulatory hurdles.

5Notable Q&A Insights

Pipeline and Trials: Questions raised about the rationale for trial designs and the competitive landscape for petosemtamab and EPKINLY, with management expressing confidence in their data and differentiation strategies.

Market Strategy: Discussions about the implications of competitors pursuing accelerated approvals and how Genmab plans to maintain its competitive edge.

Intellectual Property: Management refrained from providing detailed insights on IP strategy but acknowledged ongoing efforts to extend patent protections. Overall, Genmab showcased strong financial results and strategic advancements in its pipeline, while also navigating competitive pressures and regulatory challenges. The company remains optimistic about upcoming data readouts and future growth opportunities.